Disease severity in subsequent pregnancies with RhD immunization: A nationwide cohort

Carolien Zwiers,Yolentha M. Slootweg,Joke M. Koelewijn,Peter C. Ligthart,Johanna G. van der Bom,Inge L. van Kamp,Enrico Lopriore,C. Ellen van der Schoot,Dick Oepkes,Masja de Haas

DOI: https://doi.org/10.1111/vox.13651

2024-05-23

Vox Sanguinis

Abstract:Background and Objectives To evaluate the severity of haemolytic disease of the foetus and newborn (HDFN) in subsequent pregnancies with RhD immunization and to identify predictive factors for severe disease. Materials and Methods Nationwide prospective cohort study, including all pregnant women with RhD antibodies. All women with at least two pregnancies with RhD antibodies and RhD‐positive foetuses were selected. The main outcome measure was the severity of HDFN in the first and subsequent pregnancy at risk. A subgroup analysis was performed for the group of women where RhD antibodies developed after giving birth to an RhD‐positive child and thus after receiving anti‐D at least twice (group A) or during the first pregnancy at risk for immunization (group B). Results Sixty‐two RhD immunized women with a total of 150 RhD‐positive children were included. The severity of HDFN increased for the whole group significantly in the subsequent pregnancy (p

hematology